Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseTumor Lysis SyndromeSubgroupICD10E88.3MeSHTumor Lysis SyndromeSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceAllopurinolBalanced Crystalloid SolutionFebuxostatRasburicaseSupportive substanceAllopurinolBalanced Crystalloid SolutionFebuxostatRasburicaseSupportive substanceAllopurinolBalanced Crystalloid SolutionFebuxostatRasburicaseSupportive substanceAllopurinolBalanced Crystalloid SolutionFebuxostatRasburicaseNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentionsupportiveRisksDiarrheaHemorrhageIncrease AminotransferasesPruritus only studiesPublicationAuthorJones GLSpina MDiseaseNeoplasien mit hohem Tumorlysesyndrom-RisikoNeoplasien mit mittlerem Tumorlysesyndrom-RisikoOriginDivision of Medical Oncology A, National Cancer Institute, Aviano, Italy, FLORENCEManchester and Derriford Hospital,Plymouth, UKProtokolle in Überarbeitung 3 protocols foundAllopurinol 100, Prevention of Tumor Lysis Syndrome in Patients at Moderate Risk (PID311 V1.1)Febuxostat 120, Prevention of Tumor Lysis Syndrome in Patients at Moderate Risk (PID3259 V1.0)Rasburicase 3, Tumor Lysis Syndrome Prophylaxis, High Risk (PID312 V2.1)
